Cyclosporin A Induces Apoptosis in Childhood Acute Lymphoblastic Leukemia Cells

By Chikako Ito, Raul C. Ribeiro, Frederick G. Behm, Susana C. Raimondi, Ching-Hon Pui, and Dario Campana

In an effort to identify novel antileukemic agents that can bypass the mechanisms of multidrug resistance, we found that cyclosporin A ([CyA] 5 \( \mu \)mol/L) produced a median cell kill of 69% (range, 47% to 85%) in seven B-lineage acute lymphoblastic leukemia (ALL) cell lines (OP-1, SUP-B15, KOPN-55bi, RS4;11, NALM6, REH, and 380) and three T-lineage ALL cell lines (MOLT4, CCRF-CEM, and CEM-C7) after 4 days of culture. At 10 \( \mu \)mol/L, median CyA toxicity was 99% (range, 88% to >99%). CyA was equally toxic to both a multidrug-resistant cell line, CEM-VLB100, which overexpresses gp-170 P-glycoprotein, and one resistant to topoisomerase II inhibitors, CEM-VM1-5, which has a mutation in the topoiso merase II gene. CyA was also toxic to primary leukemic cells maintained in stroma-based culture, a system that substantially prolongs in vitro cell survival. Against lymphoblasts from 21 patients with B-lineage ALL, the compound (at 5 \( \mu \)mol/L) reduced the leukemic cell number by a median of 87% (range, 27% to >99%) compared with results for parallel control cultures lacking CyA. Seven of these samples were from cases with unfavorable genetic features (eg, Philadelphia-chromosome or MLL gene rearrangements); three were obtained at relapse. Against T lymphoblasts (from six patients), the median reduction in cell number was 79% (range, 30% to >99%). At 10 \( \mu \)mol/L, the cell kill exceeded 97% in all cases studied. The mechanism of CyA cytotoxicity was found to be the activation of apoptosis, which was suppressed by phosphorib myristate acetate but not by inhibitors of ceramide-mediated apoptosis, phosphatidyl inositol-3 kinase activity, or tyrosine kinase activity. These findings demonstrate high levels of CyA-induced toxicity against ALL cells at concentrations achievable in vivo, thus providing a strong rationale for clinical testing of this agent in patients with ALL.

SUBJECTS AND METHODS

Patients and cell lines. Bone marrow cells were collected at diagnosis or relapse from 27 patients with ALL (21 B-lineage and six T-lineage cases) aged 7 months to 16 years (median, 8 years; Table 1). Bone marrow cells from three healthy donors were also studied. Approval for these studies was obtained from the St. Jude Institutional Review Board, with informed consent given by the parents or guardians of each child. In all B-lineage cases, more than 80% of the lymphoblasts were positive for CD19, class II antigens, and terminal deoxynucleotidyl transferase (TdT) and lacked surface Igs. Six of 21 cases were classified as pre-B ALL, with lymphoblasts expressing cytoplasmic \( \mu \) heavy chains. In T-lineage cases, more than 80% of the cells were positive for CD7, cytoplasmic or surface CD3, and TdT. In all T-lineage ALL cases, drug testing was performed immediately after cell collection, whereas B-lineage ALL samples were used either fresh or after cryopreservation; previous experiments have shown that the latter does not affect the ability of these cells to grow in stroma-supported cultures.11 In all experiments, cell viability exceeded 80% by trypan blue dye exclusion.

Mononuclear cells were collected by density-gradient centrifugation (Lymphoprep; Nycomed, Oslo, Norway) and washed three times in phosphate-buffered saline (PBS) and once in AIM-V (GIBCO, Grand Island, NY), a chemically defined, serum-free, cytokine-free tissue culture medium. The ALL cell lines selected for this study (OP-1, SUP-B15, KOPN-55bi, RS4;11, NALM6, REH, 380, CCRF-CEM, CEM-C7, and MOLT4) are maintained in our laboratory, and the cell lines CEM-VLB100 and CEM-VM1-5 were provided by Dr W.M. Beck, University of Illinois Cancer Center (Chicago, IL).16,17 All cell lines were maintained in RPMI 1640 tissue culture medium (Whitaker Bioproducts, Walkersville, MD) with 10% fetal calf serum (Whitaker).
Cultures were incubated at 37°C with 5% CO₂ and 90% humidity for phosphate, staurosporine, and genistein were purchased from Sigma. MO). Phorbol myristate acetate, fumonisin B₁, sphingosine 1-
land was also used. Teniposide was obtained from Bristol Myers
for intravenous administration (Sandimmune; Sandoz, Basel, Switzer-
tations indicated in the results. In some experiments, a CyA preparation
immediately before it was added to the cultures at the final concentra-
solution, 5 mmol/L) and further diluted in AIM-V or RPMI 1640

Cells were plated in each well in the absence of stroma. CyA
immediately before it was added to the cultures at the final concentra-

1002 ITO ET AL

<table>
<thead>
<tr>
<th>Patient No.</th>
<th>Age (yr)</th>
<th>Immunophenotype</th>
<th>Karyotype</th>
</tr>
</thead>
<tbody>
<tr>
<td>1*</td>
<td>5</td>
<td>Early B</td>
<td>46,XY,t(9;22)(q34;q11.2)[19]</td>
</tr>
<tr>
<td>2</td>
<td>8</td>
<td>Early B</td>
<td>46,XY,t(9;22)(q34;q11.2)[23]#</td>
</tr>
<tr>
<td>3*</td>
<td>8</td>
<td>Early B</td>
<td>46,XY,t(9;22)(q34;q11.2)[16]#</td>
</tr>
<tr>
<td>4*</td>
<td>14</td>
<td>Pre-B</td>
<td>46,XX,t(4;11)(q21;q23)[22]</td>
</tr>
<tr>
<td>5</td>
<td>15</td>
<td>Pre-B</td>
<td>47,XY, + t(4;11)(q21;q23)[10]/46,idem, -X[9]/46,XY[5]#</td>
</tr>
<tr>
<td>6</td>
<td>&lt;1</td>
<td>Pre-B</td>
<td>46,XY,t(4;11)(q21;q23)[11]/46,XY[10]#</td>
</tr>
<tr>
<td>7</td>
<td>9</td>
<td>Early B</td>
<td>47,XY, + t(11;19)(q23;p13.3)[22]/46,XY[4]#</td>
</tr>
<tr>
<td>8</td>
<td>3</td>
<td>Early B</td>
<td>46,XX[3][1]#</td>
</tr>
<tr>
<td>9</td>
<td>2</td>
<td>Pre-B</td>
<td>46,XY,add(8)(p21)[10]/46,XY,t(9;11)(p22;q23)[11]/46,XY[4]#</td>
</tr>
<tr>
<td>10</td>
<td>8</td>
<td>Early B</td>
<td>46,XY,del<a href="p13">9</a>;t(9;13)[12]/46,XY[16]</td>
</tr>
<tr>
<td>11</td>
<td>4</td>
<td>Early B</td>
<td>47,XY, + 21[3]/46,XY,del(9p21)[2]</td>
</tr>
<tr>
<td>12</td>
<td>8</td>
<td>Early B</td>
<td>29,XY, + 4, + 8, + 18, + 21, + mar[5]/57,XY, + X, + ?Y, + 4, + 5,del(5)(p13),?del(6)(q21), + 6, + 8, + 9, + 14, + 18, + 21, + mar[6]</td>
</tr>
<tr>
<td>13</td>
<td>15</td>
<td>Pre-B</td>
<td>46,XY,del<a href="q21q26">3</a>[9]/46,XY[5]</td>
</tr>
<tr>
<td>14</td>
<td>6</td>
<td>Pre-B</td>
<td>47,XX, + 10,del(11)(q23);t(11;12)[p22;p13],t(4;12)[q21;p13][7]/45,XY, - X, t(4;12)[q21;p13][2]#</td>
</tr>
<tr>
<td>15</td>
<td>1</td>
<td>Early B</td>
<td>45,XX, - 7,del(1q32),der(127)(7;12)[q11;p13][10]/46,XX[8]#</td>
</tr>
<tr>
<td>16</td>
<td>14</td>
<td>Early B</td>
<td>46,XX[23]</td>
</tr>
<tr>
<td>17</td>
<td>14</td>
<td>Early B</td>
<td>46,XX,del[11q32]/46,XX[24#]</td>
</tr>
<tr>
<td>18</td>
<td>3</td>
<td>Early B</td>
<td>46,XX,add(21p11)[10]/46,XX[10]</td>
</tr>
<tr>
<td>19</td>
<td>8</td>
<td>Early B</td>
<td>46,XX,t(8;9)(q12-13;p22);t(15;19)[q15;p13][19]/46,idem, - 14, + mar[1]</td>
</tr>
<tr>
<td>20</td>
<td>3</td>
<td>Early B</td>
<td>48,XY, + 10,add(12)[p13], + 21[22]/46,XY[4]#</td>
</tr>
<tr>
<td>21</td>
<td>3</td>
<td>Early B</td>
<td>47,XY,add(19)[p13], + 21[6]/46,XY[17]</td>
</tr>
<tr>
<td>22</td>
<td>5</td>
<td>T</td>
<td>46,XY,add(19)[p13][5]/46,XY[12]</td>
</tr>
<tr>
<td>23</td>
<td>12</td>
<td>T</td>
<td>46,XY[50]</td>
</tr>
<tr>
<td>24</td>
<td>4</td>
<td>T</td>
<td>45,XY,del[11q14q23];add(12)[p11.2], - 18[11]/45,idem, der(16)t(1;16)[q21;q11.2][5]</td>
</tr>
<tr>
<td>25</td>
<td>4</td>
<td>T</td>
<td>ND</td>
</tr>
<tr>
<td>26</td>
<td>16</td>
<td>T</td>
<td>46,XY,del(6)[q15q21][5]/46,XY[5]</td>
</tr>
<tr>
<td>27</td>
<td>12</td>
<td>T</td>
<td>46,XX[29]</td>
</tr>
</tbody>
</table>

Abbreviation: ND, not determined.
*Early B: CD19+, CD10+ or CD10−; Pre-B: same, but with cytoplasmic µ; T: CD7+, cytoplasmic or surface CD3+.
†Karyotypes previously reported.

Cell culture and treatment with CyA. Bone marrow stromal cells
depleted of T cells by CD6/CD8-mediated rabbit complement lysis
were derived from seven normal donors (5 to 26 years old) and prepared
in 96-well flat-bottomed plates (Costar, Cambridge, MA) as previously
described. To prepare test cultures, we removed the media from the
bone marrow stroma and washed the adherent cells seven times with
AIM-V tissue culture medium. Leukemic lymphoblasts or normal bone
marrow cells were resuspended in AIM-V, and 1 to 3 × 10⁶ cells were
placed on the stromal layer in each well. Continuously growing cell
lines were resuspended in RPMI 1640 with additives, and 1 to 3 × 10⁶
cells were plated in each well in the absence of stroma. CyA
(Calbiochem Inc, San Diego, CA) was diluted in absolute ethanol (stock
solution, 5 mmol/L) and further diluted in AIM-V or RPMI 1640
immediately before it was added to the cultures at the final concentra-
tions indicated in the results. In some experiments, a CyA preparation
for intravenous administration (Sandimmune; Sandoz, Basel, Switzerland)
was also used. Teniposide was obtained from Bristol Myers
Squibb (Walliford, CT) and daunorubicin from Sigma (St Louis,
MO). Phorbol myristate acetate, fumonisin B₁, sphingosine 1-
phosphate, staurosporine, and genistein were purchased from Sigma.
 Cultures were incubated at 37°C with 5% CO₂ and 90% humidity for
the times indicated in the results.

Assessment of drug effects. At the beginning and end of the
cultures, the cell number and immunophenotype were determined by
flow cytometry. Briefly, cultures were transferred to Falcon tubes
(Becton Dickinson, Lincoln Park, NJ). Cells from B-lineage cases
were incubated with CD19 (Leu 12) monoclonal antibody conjugated to
fluorescein isothiocyanate (FITC), and those from T-lineage cases with
CD7-FITC. Normal bone marrow cells were labeled with CD34
conjugated to peridin chlorophyll protein, CD19 PE, as well as with
CD13 and CD33 conjugated to FITC. All monoclonal antibodies and
isotype-matched unreactive controls were purchased from Becton
Dickinson (San Jose, CA) or Dako (Carpinteria, CA). Staining with
antibodies was omitted in experiments with cell lines. After two washes
in PBS with 0.2% bovine serum albumin and 0.2% sodium azide, the
cells were resuspended in 0.5% paraformaldehyde and analyzed with a
FACScan flow cytometer and Cell Quest software (Becton Dickinson).
In each case, we outlined “gates” surrounding the area of the
light-scatter dot plot that comprised all viable leukemic cells, and used
them to enumerate cells that were present before and after culture with
or without CyA. For primary leukemias and normal bone marrow cells,
the results were corrected for the percentage of cells in each sample
expressing different antigens. The formula, (no. of cells recovered
with CyA/no. of cells recovered without CyA) × 100, was used to calculate
relative cell recovery after CyA treatment. All results are reported as
the mean of duplicate experiments. Drug concentrations that produced 50%
cell killing (LC₅₀) were calculated with the AllFit software from the
National Institutes of Health. DNA gel electrophoresis to detect apoptotic DNA fragmentation was performed after separating fragmented and intact DNA by centrifuga-
tion as previously described. We also studied cell labeling by An-
exin-V conjugated to FITC (Trevigen, Gaithersburg, MD), which binds to phosphatidylserine exposed on the surface membrane of cells.
undergoing apoptosis. Cell membrane permeabilization was detected by standard propidium iodide labeling.

RESULTS

Toxicity against leukemic cell lines. CyA at 5 µmol/L was markedly toxic to all of the leukemic cell lines studied (Table 2). After 4 days of culture, the median percentage of cell kill among the seven B-lineage lines (OP-1, SUP-B15, KOPN-55bi, RS4;11, NALM6, REH, and 380) and the three T-lineage lines (MOLT4, CCRF-CEM, and CEM-C7) was 69% (range, 47% to 85%). The extent of CyA cytotoxicity was dose-dependent in each of these cell lines (Table 2). At 10 µmol/L, CyA was highly cytotoxic against all lines, with a median cell kill of 99% (range, 88% to >99%) after 4 days of incubation. With most of the cell lines, CyA-induced toxicity was still appreciable when the drug was added at a concentration of 2 µmol/L (median, 36%; range, 10% to 73%). In cultures containing vehicle only (0.1% ethanol), the number of cells recovered was identical to that of control cultures without additives (data not shown). In comparative experiments, the antileukemic potency of CyA from Calbiochem diluted in ethanol and the CyA preparation for clinical use (Sandimmune) was identical (data not shown). In the three B-lineage cases with adverse genetic features (no. 1 to 7), including t(9;22), t(4;11), or t(11;19),20 were susceptible to CyA (at 5 µmol/L) to the extent that the levels of cell kill did not differ significantly from those determined in other B-lineage cases: median, 95% (range, 67% to >99%) versus 85% (27% to >99%) at 5 µmol/L, and 29% (12% to 59%) versus 33% (<1% to 61%) at 2 µmol/L. Notably, three of the samples with high-risk genetic features (no. 1, 3, and 4) were obtained at relapse. Likewise, the four cell lines with t(9;22) (OP-1, SUP-B15, and KOPN-55bi) or t(4;11) (RS4;11) were as susceptible to CyA cytotoxicity as cell lines without these high-risk features (Table 2).

To determine whether CyA cytotoxicity represented a direct effect on leukemic lymphoblasts or an indirect effect mediated by damage to stromal layers, we incubated the stromal layers with CyA at various concentrations (1 to 10 µmol/L) for 2 days, washed them, and then seeded them with leukemic lymphoblasts. In two independent experiments with samples from advantage of a stroma-based culture system that allows prolonged culture. After 7 days of such culture, the median cell recovery among 27 cases studied was 103% (range, 50% to 550%). CyA at 5 µmol/L produced variable levels of cytotoxicity in these cases (Fig 1). Against B-lineage ALL (21 cases), the reduction in leukemic cell number was 27% to more than 99% (median, 87%) of that in parallel 7-day cultures not exposed to the compound but containing 0.1% ethanol (the CyA vehicle). Likewise, CyA at 5 µmol/L was cytotoxic in all six cases of T-cell ALL (range of cell kill, 30% to >99%; median, 79%; Fig 1). CyA cytotoxicity was dose-dependent, and in some cases remained substantial at concentrations as low as 1 µmol/L. At 2 µmol/L, CyA, the percentage of cell kill for 20 cases of B-lineage ALL was 12% to 61% (median, 32%). Cytotoxicity was not detectable at this concentration in only one case. Similar levels of cell kill were obtained at this drug concentration in T-cell samples (median, 58%; range, 16% to 83%).

Cells from the seven B-lineage ALL cases with adverse genetic features (no. 1 to 7), including t(9;22), t(4;11), or t(11;19),20 were susceptible to CyA (at 5 µmol/L) to the extent that the levels of cell kill did not differ significantly from those determined in other B-lineage cases: median, 95% (range, 67% to >99%) versus 85% (27% to >99%) at 5 µmol/L, and 29% (12% to 59%) versus 33% (<1% to 61%) at 2 µmol/L. Notably, three of the samples with high-risk genetic features (no. 1, 3, and 4) were obtained at relapse. Likewise, the four cell lines with t(9;22) (OP-1, SUP-B15, and KOPN-55bi) or t(4;11) (RS4;11) were as susceptible to CyA cytotoxicity as cell lines without these high-risk features (Table 2).

To determine whether CyA cytotoxicity represented a direct effect on leukemic lymphoblasts or an indirect effect mediated by damage to stromal layers, we incubated the stromal layers with CyA at various concentrations (1 to 10 µmol/L) for 2 days, washed them, and then seeded them with leukemic lymphoblasts. In two independent experiments with samples from...
patients no. 4 and 8, the percentage of cell recovery after 7 days of culture on CyA-pretreated stroma was identical to that achieved with unmanipulated stromal layers. For example, the percentage of cell recovery after culture on unmanipulated stroma was 111% and 103% in the two cases; after culture on stroma pretreated with CyA 5 µmol/L, it was 111% and 102%, respectively. Thus, any indirect toxicity to stromal layers does not appear to influence the recovery of ALL cells exposed to CyA.

Toxity against normal immature hematopoietic cells. Previous studies with colony-forming assays have indicated that CyA has no toxicity against normal hematopoietic cells.21-24 To further address this issue, we prepared stroma-supported cultures of normal bone marrow mononucleated cells from three individuals with and without CyA, and assessed the effects of the compound on the expansion of phenotypically immature cells characterized by low side-scatter, expression of CD34, and absence of markers associated with B-lineage (CD19) or cells characterized by low side-scatter, expression of CD34, and the compound on the expansion of phenotypically immature further address this issue, we prepared stroma-supported cul-

To investigate the signaling pathways leading to apoptosis in leukemic cells exposed to CyA, we used a series of compounds that have been reported to inhibit apoptosis induced by a variety of stimuli. Phorbol myristate acetate (1 to 10 ng/mL), which stimulates protein kinase C activity and inhibits radiation- and glucocorticoid-induced apoptosis,29,30 suppressed the toxic effects of CyA on the pre-B ALL cell line NALM6 (Fig 3) and in the T-cell line MOLT4 (not shown). All other compounds tested at nontoxic concentrations, including the ceramide-mediates apoptosis inhibitors fumonisin B1 (1 to 50 µmol/L) and sphingosine-1-phosphate (0.1 to 10 µmol/L),31,33 the phosphati-
dyl inositol-3 kinase inhibitor wortmannin (100 nmol/L),24,36 and the tyrosine kinase inhibitors staurosporine (3 to 50 nmol/L) and genistein (1 to 50 nmol/L).27 lacked any discernible effect on CyA-induced cytotoxicity in both cell lines (Fig 3, and not shown).

DISCUSSION

In this study, we found that CyA is toxic to leukemic lymphoblasts via induction of apoptosis, which was detectable as early as 24 hours after exposure of the cells to the drug. Although previous studies had indicated that CyA selectively produces toxicity in T cells,3,6 we did not find its effects to be restricted to cells of this lineage. To the contrary, the compound was equally active against B and T lymphoblasts; moreover, both continuously growing cell lines and fresh samples of leukemic cells from patients were susceptible to the toxic effects of CyA. Although the toxicity of CyA observed on primary leukemic cells could be due to an effect of the compound on the stromal layers used to support ALL cell survival in vitro, we think this indirect mechanism unlikely, as our experiments using stroma pretreated with CyA failed to reveal a decrease in its capacity to promote ALL cell survival. In addition, the cytotoxic effects of CyA were also observed in the ALL cell lines growing in vitro without stromal cells.

The suppressive effects of CyA on normal lymphocyte function include inhibition of T-cell activation in vitro in response to mitogenic lectins, CD3 ligation, phorbol ester, and Ca\(^{2+}\) ionophore,1,2 such as FK-506 and rapamycin,37 as well as suppression of B-cell activation in response to B-cell receptor cross-linking.29 Notably, treatment of murine splenic B cells with CyA induces cell death.39 Our findings indicate that CyA also suppresses the growth of malignant human lymphoid cells. The precise biochemical mechanisms underlying CyA-induced apoptosis in leukemic lymphoblasts remain to be clarified, but appear to be, at least in part, distinct from those operating in cells undergoing apoptosis after exposure to tumor necrosis factor,31,32 daunorubicin,33 and ligation of Fas,32,37 surface Ig,35 or CD38,36 as inhibitors that rescue cells from these agents failed to diminish CyA toxicity. Nevertheless, CyA toxicity was markedly suppressed by exposure to phorbol ester, reminiscent of observations with radiation- and steroid-induced apoptosis in thymocytes.29,30 Interestingly, other compounds known to interfere with Ca\(^{2+}\)-mediated signaling and T-cell activation,1,2 such as FK-506 and rapamycin, did not induce apoptosis in ALL cells (our unpublished observation, September 1996). FK-506, which is approximately 100-fold more active than CyA in inhibiting T-cell activation, had no effect on leukemic cell growth or survival,6 while rapamycin had a cytostatic but not cytotoxic activity against ALL cell lines.

Our findings have clear clinical implications. Currently, about 30% of children and 65% of adults with ALL can be expected to relapse one or more times.40 Patients with the Philadelphia-chromosome or 11q23 abnormalities involving the MLL gene, representing approximately 6% of children and 30% of adults with ALL, have an especially dire prognosis.40 Thus, new antileukemic agents capable of overcoming the different mechanisms of drug resistance are urgently needed. It is noteworthy in this regard that all of our cases, including those studied at relapse and/or displaying adverse cytogenetic features, as well as cell lines with molecular features directly

From www.bloodjournal.org by guest on July 15, 2017. For personal use only.
linked to multidrug resistance, were susceptible to CyA-induced apoptosis.

The findings of CyA antileukemic activity in this study complement previous observations that CyA increases the sensitivity of multidrug-resistant cells to anticancer agents through a specific interaction of CyA with the 170-kD drug-efflux pump P-glycoprotein.41,42 For example, in experiments with mice engrafted with L1210 lymphoid leukemia and treated with etoposide, the addition of CyA significantly prolonged survival.43 Of note, in our study, the cell line CEM-VLB 100, which overexpresses P-glycoprotein, was nevertheless susceptible to CyA-induced apoptosis. Clinical trials of CyA administered intravenously as a modulator of drug resistance have shown that steady-state serum levels of 3 to 5 µmol/L,44,45
these compounds were markedly toxic. Bars represent the mean ± SD of 4 measurements per test.

which are cytotoxic in vitro, are readily achieved at tolerable administered doses. The unique antileukemic activity of CyA, which may bypass the common mechanisms of drug resistance, and its relatively lower toxicity against immature normal hematopoietic cells of T cells provide a strong rationale for clinical testing of this agent in patients with high-risk ALL.

ACKNOWLEDGMENT

We thank Elaine Coustan-Smith for flow-cytometric analysis of apoptosis and John Gilbert for editorial assistance.

REFERENCES

Cyclosporin A Induces Apoptosis in Childhood Acute Lymphoblastic Leukemia Cells

Chikako Ito, Raul C. Ribeiro, Frederick G. Behm, Susana C. Raimondi, Ching-Hon Pui and Dario Campana